Dr Reddy's Labs

Dr Reddy's enters hormone replacement therapy segment with $32 mn buy

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

Wegovy copycat to be priced competitively with 50-60% discounts: Dr Reddy's

Wegovy's monthly price in India ranges from ₹10,850 ($119.65) for the lowest 0.25 mg dose to ₹16,400 for the highest 2.4 mg dose

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

USFDA's new biosimilar norms to woo more players, fast-track mkt entry

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

Here's what brokerages expect from Dr Reddy's Labs ahead of Q1 show

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Dr Reddy's declines 3% after China's regulator bans import of ADHD drug

Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.

Dr Reddy's Lab says its Andhra plant gets two observations from USFDA

Dr Reddy's Laboratories Ltd on Thursday said the US health regulator has issued Form 483 with two observations after inspecting its manufacturing facility located at Srikakulam in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The US Food and Drug Administration (USFDA) completed a pre-approval inspection at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh on Thursday, Dr Reddy's said in a regulatory filing. The inspection was conducted from June 30, 2022 to July 7, 2022. "We have been issued a Form 483 with two observations, which we will address within the stipulated timeline," the company added.

Dr Reddy's subsidiary inks pact with US-based Olema Pharmaceuticals

Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of a target

Dr Reddy's seeks nod for phase-3 trial of Sputnik Light as booster dose

Sputnik Light has not yet received emergency use authorisation from the DCGI

Top trading ideas by Ajit Mishra: Buy Asian Paints, IDFC First Bank

The overall chart pattern of Asian Paints indicates that the prevailing momentum is likely to continue

Dr Reddy's reclaims spot as India's 2nd most valuable pharma company

At 02:17 pm, Dr Reddy's Labs market cap stood at Rs 90,348 crore while that of Divi's Laboratories stood at Rs 89,119 crore, BSE data show

Dr Reddy's Labs advances 4%, hits a record high on healthy Q1 numbers

The company's consolidated revenues rose 15 per cent to Rs 4,418 crore, mainly due to growth in US formulations

Market Ahead, May 11: Top factors that could guide markets this week

Around 50 companies including the likes of Maruti Suzuki, Nestle, Dr Reddy's Labs, Biocon, and Bandhan Bank are scheduled to announce their March quarter results.

PSAI segment decline pulls down Dr Reddy's Q1 show

Earnings were driven by one-off gains

US Supreme Court allows Dr Reddy's Labs to sell generic Suboxone film

The potential revenue upside from the sale of generic Suboxone is expected to be substantial for Dr Reddy's when it resumes sales

US court rules in favour of Dr Reddy's, allows sale of generic Suboxone

According to market reports, suboxone had sales of around $1.86 billion in the US for the 12 months ended April